Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-11-07 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
八届十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details decisions made at the 14th meeting of the 8th board, including approval of installment payments for convertible preferred shares, establishment of joint ventures, amendments to the company charter, and scheduling of an extraordinary general meeting. The content focuses on board decisions and corporate governance matters rather than financial results or reports. It is not a full annual or interim report, nor an earnings release or audit report. The document is an official announcement of board resolutions, which fits the category of Board/Management Information (MANG). The document length is short (1282 characters), and it contains substantive content about board decisions, not just a notice or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is MANG with high confidence.
2018-11-07 Chinese
独立董事关于对外投资成立合资公司暨关联交易事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a company's external investment to establish a joint venture and related party transaction. It references compliance with stock exchange listing rules and company governance documents. The content is about approval and opinion on a specific transaction, not a financial report, earnings release, or management discussion. It is not a report publication announcement or certification letter but a governance-related document concerning board-level approval of a transaction. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management regarding company matters.
2018-11-07 Chinese
独立董事关于对外投资成立合资公司暨关联交易的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding an external investment and related party transaction. It references compliance with regulatory rules and company bylaws, and it is a formal statement of approval and fairness of a specific transaction. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or capital update. It is a governance-related document concerning board decisions and compliance with regulations on related party transactions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management information.
2018-11-07 Chinese
章程（2018年11月修订版）
Governance Information Classification · 100% confidence The document is titled "章程" which translates to "Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, shareholder meetings, share issuance, share transfer, and other governance matters. The content is focused on the internal rules and governance framework of the company rather than financial performance, audit results, or meeting announcements. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. The document is a comprehensive governance document that outlines the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR).
2018-11-07 Chinese
八届十三次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It reports the approval of the 2018 third quarter report and a change in accounting policy by the board of directors. The document is short (647 characters) and primarily announces board decisions rather than providing the full quarterly report or detailed financial data. It also references a separate announcement on the Shanghai Stock Exchange website for details. Therefore, this document is best classified as Board/Management Information (MANG) because it concerns board meeting resolutions and approvals, not the full interim report itself.
2018-10-29 Chinese
八届六次监事会决议公告
Regulatory Filings Classification · 90% confidence The document is a supervisory board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It discusses the approval of changes in accounting policies and provides an audit opinion on the 2018 third quarter report. The document is short (826 characters) and primarily serves as an official announcement of the supervisory board's review and approval of the quarterly report rather than containing the full financial statements or detailed financial data itself. It also includes assurances about the accuracy and completeness of the report. Given the length and content, this is not the full Interim/Quarterly Report (IR) but rather an announcement related to it. Therefore, it fits best under Regulatory Filings (RNS) as a formal disclosure of supervisory board decisions and opinions on the quarterly report.
2018-10-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.